The Union Budget 2026–27 has introduced a wave of optimism across India’s healthcare and pharmaceutical sectors, centered on the landmark Rs. 10,000 crore BioPharma Shakti initiative and a strategic push for medical value tourism.
From strengthening domestic biologics manufacturing to expanding the mental health and allied workforce, the budget's provisions aim to transition India from a volume-driven ‘pharmacy of the world’ to an innovation-led global health hub, health experts comment.
Dr. K. Anand Kumar, MD of Indian Immunologicals Ltd, emphasized that the BioPharma Shakti initiative arrives at a defining moment to solidify India’s role as a global vaccine and biologics manufacturing leader. He noted that targeted investments in high-containment facilities and indigenous raw materials like culture media and adjuvants will significantly bolster supply chain resilience, helping India evolve into a trusted hub for health security.
Dr. Puneet Khanduja, head of health and nutrition at MicroSave Consulting (MSC), described the budget as a decisive shift toward systemic reform. He highlighted the institutional scaling of both modern and traditional systems, specifically noting that the expansion of NIPER and the strengthening of the WHO Global Traditional Medicine Centre in Jamnagar will position India’s traditional medicine within global wellness systems, provided quality frameworks are strictly reinforced.
Abhay Soni, chairman and managing director of Max Healthcare, welcomed the proposal to establish five regional medical hubs as a strategic step for medical value travel. He pointed out that by integrating clinical care with research, Ayush, and rehabilitation, India can leverage its world-class infrastructure and cost advantage to become a top destination for international patients, while simultaneously creating massive employment for doctors and allied professionals.
Gautam Bali, managing director of Vestige Marketing Pvt Ltd, viewed the budget as a reaffirmation of people-led entrepreneurship. He noted that the focus on Yuva Shakti, skilling, and the SHE-MARTs initiative creates a supportive framework for the direct selling industry and rural women entrepreneurs, particularly in Tier II and Tier III markets, fostering inclusive and resilient economic growth.
Priyanka Aggarwal, managing director and senior partner at BCG, highlighted the budget's recognition of the rising burden of non-communicable diseases. She stated that the creation of 1,000 accredited clinical trial sites and the strengthening of regulatory capacities will help India transition from a generics-led model to high-value biologics, ultimately improving domestic R&D depth and clinical development timelines.
Sameer Merchant, CEO and MD of Laxmi Dental Limited, noted that the focus on workforce development, particularly the training of 1.5 lakh caregivers, is a thoughtful approach to improving healthcare quality and resilience. He believes these measures will ensure balanced healthcare access beyond metropolitan centers, supporting specialized segments that depend heavily on skilled institutional capacity.
Abhimanyu Roy, executive director at Avalon Consulting, praised the continued focus on building ecosystem capacity through medical tourism hubs. He also observed that the budget’s emphasis on electronics and semiconductor manufacturing would indirectly benefit the medical devices industry by accelerating the localization of electronic medical components and devices.
Sudipta Sengupta, founder and CEO of The Healthy Indian Project (THIP), remarked that the budget acknowledges health literacy as vital infrastructure. By investing in emergency and trauma care centers at the district level and training multiskilled caregivers, the government is reinforcing the idea that empowered, well-informed citizens are the first line of care in a robust healthcare system.
Gaurav Soni, Founder and managing director of Botanic Healthcare, stated that the budget signals an intent to move from volume-led manufacturing to value-driven growth. While praising the focus on science-backed wellness, he suggested that clearer regulatory pathways and targeted fiscal incentives for the nutraceutical industry would further accelerate global competitiveness.
Dr. Simon Thomas, senior director at Max Super Speciality Hospital, Shalimar Bagh, highlighted how the Biopharma Shakti initiative will transform the management of chronic conditions. He noted that domestic production of biologics will improve affordability for targeted therapies in cancer and autoimmune disorders, and potentially even support regenerative treatments like cartilage regeneration to delay knee replacements.
Dr. Harsh Mahajan, mentor at FICCI Health and founder of Mahajan Imaging & Labs, pointed out the direct benefits for diagnostic service providers. He explained that the push for advanced biologics will increase the demand for high-quality diagnostics to monitor treatments, while the new regional hubs offer labs fresh opportunities to expand services and collaborate on research.
Dr. Rakesh Gupta, chairman of Sarvodaya HealthCare, hailed the exemption of customs duty on 17 life-saving cancer drugs as a compassionate move that alleviates the crushing financial burden on families. He emphasized that combining these cost-saving measures with a highly skilled workforce of 1.5 lakh newly trained caregivers will provide a strong foundation for a data-driven, holistic healthcare approach.
Dr. Dharminder Nagar, managing director of Paras Health and FICCI Co-chair, concluded that the budget brings tangible relief to patients in Tier 2 and Tier 3 cities. By reducing the cost of critical therapies through duty exemptions and encouraging domestic biosimilar manufacturing, the government is ensuring that advanced care is no longer restricted to those who can afford to travel to major metros. |